G2167

Gliclazide

powder, ≥98%

• Synonym(s): 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea
• Empirical Formula (Hill Notation): C₁₅H₂₁N₃O₃S
• CAS Number: 21187-98-4
• Molecular Weight: 323.41
• NACRES: NA.77
• PubChem Substance ID: 24895090
• UNSPSC Code: 12352125
• EC Number: 244-260-5
• MDL number: MFCD00409893
• Assay: ≥98%
• Form: powder

Properties

• Quality Segment: 200
• assay: ≥98%
• form: powder
• color: white
• mp: 163-169 °C (lit.)
• solubility: methylene chloride: soluble
• originator: Servier
• SMILES string: Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
• InChI: 1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
• InChI key: BOVGTQGAOIONJV-UHFFFAOYSA-N
• Gene Information: human ... KCNJ1(3758)

Description

Application

Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Gliclazide has been used:

• to study its antiglycative properties and to study its effects on the glycation of bovine serum albumin (BSA) structure[1]
• as a reference standard in solid-phase extraction (SPE) followed by instrumental analysis using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) for the quantification of water samples[2]
• to develop and validate a simple, sensitive, rapid, economic and isocratic high-performance liquid chromatography (HPLC) method for the determination of gliclazide

Biochem/physiol Actions

Gliclazide is Kir6.2/SUR1 channel inhibitor.

Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases

Features and Benefits

This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)